34. 神経線維腫症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 165 / 薬物数 : 189 - (DrugBank : 83) / 標的遺伝子数 : 93 - 標的パスウェイ数 : 209
薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
1064NM laser
Massachusetts General Hospital
2021 Phase 1 NCT04730583 United States
1064NM ND:YAG laser
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2024 Phase 1 NCT06132165 United States
2-amino-4-(methyl[11C]sulfanyl)butanoic acid
Guys' and St. Thomas' NHS Foundation Trust
2011 - EUCTR2010-019759-23-GB United Kingdom
755NM alexandrite laser
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2024 Phase 1 NCT06132165 United States
2021 Phase 1 NCT04730583 United States
89ZR-bevacizumab
Leiden University Medical Center
2021 Phase 2 EUCTR2020-000156-35-NL Netherlands
Abemaciclib
National Cancer Institute (NCI)
2021 Phase 1/Phase 2 NCT04750928 United States
Acetaminophen
AstraZeneca
2018 Phase 1 NCT03649165 United States
Acetylcysteine
Children's Hospital Medical Center, Cincinnati
2019 Phase 2 NCT04481035 United States
Afinitor
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2011-002228-42-FR France
New York University School of Medicine
2011 Phase 2 NCT01419639 United States
AL2846 capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021 Phase 1/Phase 2 NCT05011019 China
Aminolevulinic acid
Donald Basel
2016 Phase 2 NCT02728388 United States
AMN107
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Antigen-specific T cells cart/CTL and dcvac
Shenzhen Geno-Immune Medical Institute
2019 Phase 1/Phase 2 NCT04085159 China
APG-115
AeRang Kim
2025 Phase 1/Phase 2 NCT06735820 United States
AR-42
Massachusetts Eye and Ear Infirmary
2015 Early Phase 1 NCT02282917 United States
Asclera
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2022 Phase 1 NCT06120036 United States
Aspirin
Massachusetts Eye and Ear Infirmary
2018 Phase 2 NCT03079999 United States
Axitinib
NYU Langone Health
2014 Phase 2 NCT02129647 United States
Azacitidine
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
AZD2014
Massachusetts General Hospital
2016 Phase 2 NCT02831257 United States
AZD6244
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
National Cancer Institute (NCI)
2011 Phase 1/Phase 2 NCT01362803 United States
Bevacizumab
Kiyoshi Saito
2019 Phase 2 JPRN-jRCT2080224914 Japan
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
National Cancer Institute (NCI)
2010 Phase 2 NCT01207687 United States
Northwestern University
2010 Phase 2 NCT01125046 United States
Sarcoma Alliance for Research through Collaboration
2012 Phase 2 NCT01661283 United States
Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of Medicine
2018 - ChiCTR1800016040 China
University of Alabama at Birmingham
2013 Phase 2 NCT01767792 United States
Bevacizumab zirconium ZR-89
Leiden University Medical Center
2022 - NCT05685836 Netherlands
2021 Phase 2 EUCTR2020-000156-35-NL Netherlands
Binimetinib
University of Alabama at Birmingham
2017 Phase 2 NCT03231306 United States
Biopsy
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000036770 China
Biospecimen collection
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2010 Phase 1/Phase 2 NCT01089101 United States
Blood sample
Assistance Publique - Hôpitaux de Paris
2024 - NCT06147414 France
Bone marrow aspiration and biopsy
National Cancer Institute (NCI)
2018 Phase 2 NCT03190915 United States
Bony toxicity
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Brigatinib
Scott R. Plotkin, MD, PhD
2020 Phase 2 NCT04374305 United States
Busulfan
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Cabozantinib
University of Alabama at Birmingham
2014 Phase 2 NCT02101736 United States
Cabozantinib oral tablet
Girish Dhall, MD
2025 Phase 1 NCT06502171 United States
Carboplatin
Children's Oncology Group
2006 Phase 1 NCT00352495 Canada;United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
Cediranib maleate
National Cancer Institute (NCI)
2006 Phase 2 NCT00326872 United States
Celecoxib
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Cetuximab
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Cholecalciferol
University of Utah
2017 Phase 2 NCT01968590 Canada;Germany;United States
Conventional surgery
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Crizotinib
Medical University of Warsaw
2023 Phase 2 EUCTR2021-005770-26-PL Poland
University of Alabama at Birmingham
2020 Phase 2 NCT04283669 United States
Curcumin
Masonic Cancer Center, University of Minnesota
2022 Phase 1 NCT05363267 United States
Cytarabine
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
Dabrafenib
Novartis Pharmaceuticals
2019 Phase 4 NCT03975829 Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
Pediatric Brain Tumor Consortium
2020 Phase 1/Phase 2 NCT04201457 United States
Deoxycholic acid
Massachusetts General Hospital
2024 Phase 1 NCT06132165 United States
Dexmedetomidine
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
Diclofenac sodium
Fundação Educacional Serra dos Órgãos
2017 Phase 2 NCT03090971 Brazil
Doxorubicin hydrochloride
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Doxycycline
Massachusetts Eye and Ear Infirmary
2022 Phase 1/Phase 2 NCT05521048 United States
Endostatin
Beijing Tiantan Hospital
2014 Phase 2 NCT02104323 China
Etoposide
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Everolimus
New York University School of Medicine
2011 Phase 2 NCT01419639 United States
Novartis Pharmaceuticals
2012 Phase 2 NCT01365468 Israel
- Phase 4 EUCTR2016-001563-36-Outside-EU/EEA Israel
Sarcoma Alliance for Research through Collaboration
2012 Phase 2 NCT01661283 United States
The University of Texas Health Science Center, Houston
2015 Phase 2 NCT02332902 United States
EVérolimus
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2011-002228-42-FR France
FCN-159
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023 Phase 1;Phase 2 EUCTR2021-001572-42-IT China;France;Italy;Poland;Spain;United States
2021 Phase 1/Phase 2 NCT04954001 China;Spain;United States
Filgrastim
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Fludarabine
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
Fludeoxyglucose F 18
Children's Hospital of Philadelphia
2002 - NCT00060008 United States
Frameshift array blood sample test
Children's National Research Institute
2019 - NCT04212351 United States
Gadolinium contrast
Washington University School of Medicine
2013 - NCT02584413 United States
Gadopentetate dimeglumine
Children's Hospital of Philadelphia
2002 - NCT00060008 United States
Genetic analysis
University Hospital, Toulouse
2009 - NCT02422732 France
Gleevec
Indiana University
2006 Phase 2 NCT01673009 United States
Kent Robertson
2012 Phase 1/Phase 2 NCT01140360 United States
Glivec 100 MG comprimidos recubiertos CON PELícula
HOSPITAL SANT JOAN DE DÉU
2010 - EUCTR2009-016922-15-ES Spain
Glivec 400 MG comprimidos recubiertos CON PELícula
HOSPITAL SANT JOAN DE DÉU
2010 - EUCTR2009-016922-15-ES Spain
Glycopyrrolate
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
HL-085
Shanghai Kechow Pharma, Inc.
2021 Phase 2 NCT05331105 China
HLX-1502
Healx Limited
2025 Phase 2 NCT06541847 United States
Hydroxychloroquine
Pediatric Brain Tumor Consortium
2020 Phase 1/Phase 2 NCT04201457 United States
Icotinib
Li Peng
2016 Phase 2 NCT02934256 China
Ifosfamide
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Imatinib
HOSPITAL SANT JOAN DE DÉU
2010 - EUCTR2009-016922-15-ES Spain
Imatinib mesylate
Indiana University
2018 Phase 2 NCT03688568 United States
St. Justine's Hospital
2014 Phase 2 NCT02177825 Canada
Imiquimod 5% cream
Massachusetts General Hospital
2009 Phase 1 NCT00865644 United States
Koselugo 10MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Koselugo 25MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Kybella
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2022 Phase 1 NCT06120036 United States
2021 Phase 1 NCT04730583 United States
Laboratory biomarker analysis
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2017 Phase 2 NCT02839720 United States
2015 Phase 1 NCT02415153 United States
2010 Phase 2 NCT01207687 United States
Lamotrigin beta
Technische Universität München, Fakultät für Medizin
2018 Phase 2 EUCTR2016-005022-10-DE Germany
Lamotrigine
Erasmus Medical Center
2014 Phase 2/Phase 3 NCT02256124 Belgium;Netherlands;Spain
Lamotrigine dispers
Erasmus MC
2018 Phase 2 EUCTR2013-003405-26-DK Belgium;Denmark;Netherlands;Spain
2017 Phase 2 EUCTR2013-003405-26-ES Belgium;Netherlands;Spain
2015 Phase 2 EUCTR2013-003405-26-BE Belgium;Denmark;Netherlands;Spain
2014 - EUCTR2013-003405-26-NL Netherlands
Lapatinib
New York University School of Medicine
2009 Phase 2 NCT00973739 United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2009 Early Phase 1 NCT00863122 United States
Lenalidomide
National Cancer Institute (NCI)
2012 Phase 2 NCT01553149 Australia;Canada;New Zealand;United States
Levetiracetam
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 1
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 2
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 3
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Lidocaine 1% injectable solution
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
Lovastatin
Technische Universität München, Fakultät für Medizin
2018 Phase 2 EUCTR2016-005022-10-DE Germany
University of Alabama at Birmingham
2009 Phase 2 NCT00853580 Australia;United States
University of California, Los Angeles
2009 Phase 1 NCT00352599 United States
Vanderbilt University
2016 Phase 2 NCT02964884 United States
Lovastatin 60 MG
University of Coimbra
2019 - NCT03826940 Portugal
Magnetic resonance imaging
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
Washington University School of Medicine
2013 - NCT02584413 United States
Mekinist
ErasmusMC
2019 Phase 2 EUCTR2019-001317-16-NL Netherlands
VO Barnmedicin, Skånes University Hospital
2018 Phase 2 EUCTR2018-001846-32-SE Sweden
Melphalan
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Methionine
Guys' and St. Thomas' NHS Foundation Trust
2011 - EUCTR2010-019759-23-GB United Kingdom
Methotrexate
Children's Hospital of Philadelphia
2001 Phase 2 NCT00030264 United States
Methylphenidate
Hospices Civils de Lyon
2004 Phase 4 NCT00169611 France
Mirdametinib
Johns Hopkins University
2024 Phase 1/Phase 2 NCT06159166 United States
SpringWorks Therapeutics, Inc.
2022 - NCT05028166 -
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
SpringWorks Therapeutics, Inc.
2019 Phase 2 NCT03962543 United States
MRI, FDG-PET/CT scans
National Cancer Institute (NCI)
2014 Phase 1 NCT02211768 United States
N-acetyl cysteine
Children's Hospital Medical Center, Cincinnati
2020 Phase 2 NCT04481048 United States
NAC
Children's Hospital Medical Center, Cincinnati
2019 Phase 2 NCT04481035 United States
Neratinib
Scott R. Plotkin, MD, PhD
2020 Phase 2 NCT04374305 United States
Neuropsychological assessments
University Hospital, Toulouse
2009 - NCT02422732 France
Nexavar
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2011-001789-16-GB United Kingdom
NFX-179 GEL
NFlection Therapeutics, Inc.
2021 Phase 2 NCT05005845 United States
2020 Phase 2 NCT04435665 United States
Nilotinib
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2010-023508-28-GB United Kingdom
Nilotinib hydrochloride monohydrate
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Nitrous oxide
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
NPC-12G GEL
Nobelpharma
2020 Phase 3 NCT04461886 Japan
Olive OIL
Masonic Cancer Center, University of Minnesota
2022 Phase 1 NCT05363267 United States
Oncolytic measles virus encoding thyroidal sodium iodide symporter
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Other academic sham tutoring
Vanderbilt University
2016 Phase 2 NCT02964884 United States
Part 1 levulan injection
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Part 1 levulan surface application twice with microneedling
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
PAS-004 tablets
Pasithea Therapeutics Corp.
2025 Phase 1 NCT06961565 Australia
PD-0325901
University of Alabama at Birmingham
2014 Phase 2 NCT02096471 United States
PEG-interferon alpha-2B
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Pharmacodynamics
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Pharmacological study
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
National Cancer Institute (NCI)
2015 Phase 1 NCT02415153 United States
2012 Phase 2 NCT01553149 Australia;Canada;New Zealand;United States
Pirfenidone
Mayo Clinic
2000 Phase 2 NCT00754780 -
National Cancer Institute (NCI)
2004 Phase 2 NCT00076102 United States
2002 Phase 1 NCT00053937 United States
Polidocanol
Massachusetts General Hospital
2024 Phase 1 NCT06132165 United States
Poly iclc
University of Alabama at Birmingham
2022 Phase 2 NCT04544007 United States
Pomalidomide
National Cancer Institute (NCI)
2015 Phase 1 NCT02415153 United States
Propofol
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
PTC299
PTC Therapeutics
2009 Phase 2 NCT00911248 United States
QOL assessment, neuropsychological
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Quality-OF-life assessment
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
2010 Phase 2 NCT01207687 United States
Questionnaire administration
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
RAD001
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2011-002228-42-FR France
Assistance Publique - Hôpitaux de Paris
2012 Phase 2 NCT01490476 France
NYU Langone Health
2013 Early Phase 1 NCT01880749 United States
New York University School of Medicine
2011 Phase 2 NCT01419639 United States
Novartis Pharmaceuticals
2012 Phase 2 NCT01365468 Israel
- Phase 4 EUCTR2016-001563-36-Outside-EU/EEA Israel
RAD001, everolimus
Jonsson Comprehensive Cancer Center
2015 Phase 2 NCT01345136 United States
RAD001: everolimus
Assistance Publique - Hôpitaux de Paris
2011 Phase 2 NCT01412892 France
Radiation therapy
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Radiographic evaluation
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Ranibizumab
Massachusetts General Hospital
2008 Phase 0 NCT00657202 United States
Rapamycin
Department of Dermatology Graduate School of Medicine, Osaka University
2014 Phase 2,3 JPRN-UMIN000015081 Japan
Reading tutoring intervention
Vanderbilt University
2016 Phase 2 NCT02964884 United States
REC-2282
Recursion Pharmaceuticals Inc.
2022 Phase 2/Phase 3 NCT05130866 United States
Rituximab
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Saline solution
Fundação Educacional Serra dos Órgãos
2017 Phase 2 NCT03090971 Brazil
Selumetinib
AeRang Kim
2025 Phase 1/Phase 2 NCT06735820 United States
AstraZeneca
2023 Phase 2 NCT05825365 China
2021 Phase 1 NCT05101148 Poland;Russian Federation;Spain;United States
2021 Phase 3 NCT04924608 Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2020 Phase 1 NCT04590235 China
2020 Phase 1 NCT04495127 Japan
2017 - NCT03259633 United States
AstraZeneca KK
2020 Phase 1 JPRN-jRCT2080225326 Japan;North America
Children's Hospital Medical Center, Cincinnati
2017 Phase 2 NCT03095248 United States
Great Ormond Street Hospital for Children NHS Foundation Trust
2019 Phase 1/Phase 2 NCT03326388 United Kingdom
Kobayashi Hiroshi
2023 Phase 1-2 JPRN-jRCT2071220074 Germany;Italy;Japan;Netherland;Russia;Spain;USA
2022 Phase 3 JPRN-jRCT2041210036 Australia;Brasil;Canada;China;France;Germany;Italy;Japan;Poland;Russia;Spain;UK;USA
National Cancer Institute (NCI)
2016 Phase 2 NCT02407405 United States
2015 Phase 2 NCT02644512 United States
2010 Phase 1/Phase 2 NCT01089101 United States
Sarcoma Alliance for Research through Collaboration
2019 Phase 2 NCT03433183 United States
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000036770 China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024 Phase 2 NCT06621082 -
2024 Phase 2 NCT06620354 -
University of Alabama at Birmingham
2025 Phase 2 NCT06188741 -
2017 Phase 2 NCT03105258 United States
West China Hospital
2025 Phase 2 NCT06763315 China
Selumetinib (AZD6244 HYD sulfate) 25MG/M2
National Cancer Institute (NCI)
2017 Phase 2 NCT03109301 United States
Selumetinib (AZD6244 HYD sulfate) 50MG/dose
National Cancer Institute (NCI)
2017 Phase 2 NCT03109301 United States
Selumetinib 10MG capsule
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib 25MG capsule
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib capsule formulation
AstraZeneca
2022 Phase 1/Phase 2 NCT05309668 Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib capsules 10MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib capsules 25MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib granule formulation
AstraZeneca
2022 Phase 1/Phase 2 NCT05309668 Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib granules IN sprinkle capsules FOR opening 5 MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
Selumetinib granules IN sprinkle capsules FOR opening 7.5 MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib HYD-sulfate
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib HYD-sulphate
Great Ormond Street Hospital
2018 Phase 1;Phase 2 EUCTR2017-002635-41-GB United Kingdom
Selumetinib oral capsule
Girish Dhall, MD
2025 Phase 1 NCT06502171 United States
Selumetinib sulfate
AstraZeneca AB
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
Great Ormond Street Hospital
2018 Phase 1;Phase 2 EUCTR2017-002635-41-GB United Kingdom
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
2017 Phase 2 NCT02839720 United States
Sevoflurane
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
Simvastatin
Erasmus MC - Department of Pediatrics
2009 - EUCTR2009-010965-22-NL Netherlands
Simvastatin 20MG/5ML oral suspension
Central Manchester University Hospitals NHS Foundation Trust
2013 Phase 2 EUCTR2012-005742-38-GB United Kingdom
Single photon emission computed tomography
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Sirolimus
Osaka University Hospital
2016 Phase 2 JPRN-UMIN000021030 Japan
Sarcoma Alliance for Research through Collaboration
2019 Phase 2 NCT03433183 United States
University of Alabama at Birmingham
2008 Phase 2 NCT00652990 United States
2008 Phase 2 NCT00634270 United States
Skincerity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States
Skinercity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States
Sodium chloride
Kiyoshi Saito
2019 Phase 2 JPRN-jRCT2080224914 Japan
Sorafenib
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2011-001789-16-GB United Kingdom
ST002
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025 - NCT06834438 China
Sunitinib
Memorial Sloan Kettering Cancer Center
2007 Phase 2 NCT00589784 United States
Sutent®/sunitinib
Indiana University
2012 Phase 2 NCT01402817 United States
Tarceva and rapamycin
Roger Packer
2007 Phase 1 NCT00901849 United States
Tasigna
Indiana University
2011 Early Phase 1 NCT01275586 United States
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2010-023508-28-GB United Kingdom
Tasigna 150MG
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Tasigna 200MG
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Tasigna 50 MG
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Temozolomide
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Temsirolimus
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Test group (group A): FCN-159 8 MG, orally, once daily
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023 Phase 3 NCT05913037 China
Tipifarnib
National Cancer Institute (NCI)
2001 Phase 2 NCT00021541 Germany;United States
Toxicity, pharmacokinetics
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Trametinib
National Cancer Institute (NCI)
2018 Phase 2 NCT03190915 United States
Novartis Pharmaceuticals
2019 Phase 4 NCT03975829 Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
Pediatric Brain Tumor Consortium
2020 Phase 1/Phase 2 NCT04201457 United States
Region Skane
2019 Phase 2 NCT03741101 Sweden
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
University of California, San Francisco
2018 Phase 2 NCT03232892 United States
Treatment A
AstraZeneca
2018 Phase 1 NCT03649165 United States
Treatment B
AstraZeneca
2018 Phase 1 NCT03649165 United States
Treatment C
AstraZeneca
2018 Phase 1 NCT03649165 United States
Treatment D
AstraZeneca
2018 Phase 1 NCT03649165 United States
Ultrasound imaging
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Unknown
Leiden University Medical Center
2021 Phase 2 EUCTR2020-000156-35-NL Netherlands
Valproic acid
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Vehicle GEL
NFlection Therapeutics, Inc.
2021 Phase 2 NCT05005845 United States
2020 Phase 2 NCT04435665 United States
Vinblastine
Children's Hospital of Philadelphia
2001 Phase 2 NCT00030264 United States
Vinblastine sulfate
Children's Oncology Group
2006 Phase 1 NCT00352495 Canada;United States
Vinblastine sulphate
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Vincristine sulfate
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Votubia
Novartis Pharmaceuticals
- Phase 4 EUCTR2016-001563-36-Outside-EU/EEA Israel
Xalkori
Medical University of Warsaw
2023 Phase 2 EUCTR2021-005770-26-PL Poland
Massachusetts General Hospital
2021 Phase 1 NCT04730583 United States
1064NM ND:YAG laser
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2024 Phase 1 NCT06132165 United States
2-amino-4-(methyl[11C]sulfanyl)butanoic acid
Guys' and St. Thomas' NHS Foundation Trust
2011 - EUCTR2010-019759-23-GB United Kingdom
755NM alexandrite laser
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2024 Phase 1 NCT06132165 United States
2021 Phase 1 NCT04730583 United States
89ZR-bevacizumab
Leiden University Medical Center
2021 Phase 2 EUCTR2020-000156-35-NL Netherlands
Abemaciclib
National Cancer Institute (NCI)
2021 Phase 1/Phase 2 NCT04750928 United States
Acetaminophen
AstraZeneca
2018 Phase 1 NCT03649165 United States
Acetylcysteine
Children's Hospital Medical Center, Cincinnati
2019 Phase 2 NCT04481035 United States
Afinitor
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2011-002228-42-FR France
New York University School of Medicine
2011 Phase 2 NCT01419639 United States
AL2846 capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021 Phase 1/Phase 2 NCT05011019 China
Aminolevulinic acid
Donald Basel
2016 Phase 2 NCT02728388 United States
AMN107
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Antigen-specific T cells cart/CTL and dcvac
Shenzhen Geno-Immune Medical Institute
2019 Phase 1/Phase 2 NCT04085159 China
APG-115
AeRang Kim
2025 Phase 1/Phase 2 NCT06735820 United States
AR-42
Massachusetts Eye and Ear Infirmary
2015 Early Phase 1 NCT02282917 United States
Asclera
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2022 Phase 1 NCT06120036 United States
Aspirin
Massachusetts Eye and Ear Infirmary
2018 Phase 2 NCT03079999 United States
Axitinib
NYU Langone Health
2014 Phase 2 NCT02129647 United States
Azacitidine
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
AZD2014
Massachusetts General Hospital
2016 Phase 2 NCT02831257 United States
AZD6244
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
National Cancer Institute (NCI)
2011 Phase 1/Phase 2 NCT01362803 United States
Bevacizumab
Kiyoshi Saito
2019 Phase 2 JPRN-jRCT2080224914 Japan
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
National Cancer Institute (NCI)
2010 Phase 2 NCT01207687 United States
Northwestern University
2010 Phase 2 NCT01125046 United States
Sarcoma Alliance for Research through Collaboration
2012 Phase 2 NCT01661283 United States
Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of Medicine
2018 - ChiCTR1800016040 China
University of Alabama at Birmingham
2013 Phase 2 NCT01767792 United States
Bevacizumab zirconium ZR-89
Leiden University Medical Center
2022 - NCT05685836 Netherlands
2021 Phase 2 EUCTR2020-000156-35-NL Netherlands
Binimetinib
University of Alabama at Birmingham
2017 Phase 2 NCT03231306 United States
Biopsy
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000036770 China
Biospecimen collection
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2010 Phase 1/Phase 2 NCT01089101 United States
Blood sample
Assistance Publique - Hôpitaux de Paris
2024 - NCT06147414 France
Bone marrow aspiration and biopsy
National Cancer Institute (NCI)
2018 Phase 2 NCT03190915 United States
Bony toxicity
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Brigatinib
Scott R. Plotkin, MD, PhD
2020 Phase 2 NCT04374305 United States
Busulfan
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Cabozantinib
University of Alabama at Birmingham
2014 Phase 2 NCT02101736 United States
Cabozantinib oral tablet
Girish Dhall, MD
2025 Phase 1 NCT06502171 United States
Carboplatin
Children's Oncology Group
2006 Phase 1 NCT00352495 Canada;United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
Cediranib maleate
National Cancer Institute (NCI)
2006 Phase 2 NCT00326872 United States
Celecoxib
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Cetuximab
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Cholecalciferol
University of Utah
2017 Phase 2 NCT01968590 Canada;Germany;United States
Conventional surgery
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Crizotinib
Medical University of Warsaw
2023 Phase 2 EUCTR2021-005770-26-PL Poland
University of Alabama at Birmingham
2020 Phase 2 NCT04283669 United States
Curcumin
Masonic Cancer Center, University of Minnesota
2022 Phase 1 NCT05363267 United States
Cytarabine
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
Dabrafenib
Novartis Pharmaceuticals
2019 Phase 4 NCT03975829 Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
Pediatric Brain Tumor Consortium
2020 Phase 1/Phase 2 NCT04201457 United States
Deoxycholic acid
Massachusetts General Hospital
2024 Phase 1 NCT06132165 United States
Dexmedetomidine
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
Diclofenac sodium
Fundação Educacional Serra dos Órgãos
2017 Phase 2 NCT03090971 Brazil
Doxorubicin hydrochloride
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Doxycycline
Massachusetts Eye and Ear Infirmary
2022 Phase 1/Phase 2 NCT05521048 United States
Endostatin
Beijing Tiantan Hospital
2014 Phase 2 NCT02104323 China
Etoposide
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Everolimus
New York University School of Medicine
2011 Phase 2 NCT01419639 United States
Novartis Pharmaceuticals
2012 Phase 2 NCT01365468 Israel
- Phase 4 EUCTR2016-001563-36-Outside-EU/EEA Israel
Sarcoma Alliance for Research through Collaboration
2012 Phase 2 NCT01661283 United States
The University of Texas Health Science Center, Houston
2015 Phase 2 NCT02332902 United States
EVérolimus
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2011-002228-42-FR France
FCN-159
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023 Phase 1;Phase 2 EUCTR2021-001572-42-IT China;France;Italy;Poland;Spain;United States
2021 Phase 1/Phase 2 NCT04954001 China;Spain;United States
Filgrastim
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Fludarabine
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
Fludeoxyglucose F 18
Children's Hospital of Philadelphia
2002 - NCT00060008 United States
Frameshift array blood sample test
Children's National Research Institute
2019 - NCT04212351 United States
Gadolinium contrast
Washington University School of Medicine
2013 - NCT02584413 United States
Gadopentetate dimeglumine
Children's Hospital of Philadelphia
2002 - NCT00060008 United States
Genetic analysis
University Hospital, Toulouse
2009 - NCT02422732 France
Gleevec
Indiana University
2006 Phase 2 NCT01673009 United States
Kent Robertson
2012 Phase 1/Phase 2 NCT01140360 United States
Glivec 100 MG comprimidos recubiertos CON PELícula
HOSPITAL SANT JOAN DE DÉU
2010 - EUCTR2009-016922-15-ES Spain
Glivec 400 MG comprimidos recubiertos CON PELícula
HOSPITAL SANT JOAN DE DÉU
2010 - EUCTR2009-016922-15-ES Spain
Glycopyrrolate
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
HL-085
Shanghai Kechow Pharma, Inc.
2021 Phase 2 NCT05331105 China
HLX-1502
Healx Limited
2025 Phase 2 NCT06541847 United States
Hydroxychloroquine
Pediatric Brain Tumor Consortium
2020 Phase 1/Phase 2 NCT04201457 United States
Icotinib
Li Peng
2016 Phase 2 NCT02934256 China
Ifosfamide
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Imatinib
HOSPITAL SANT JOAN DE DÉU
2010 - EUCTR2009-016922-15-ES Spain
Imatinib mesylate
Indiana University
2018 Phase 2 NCT03688568 United States
St. Justine's Hospital
2014 Phase 2 NCT02177825 Canada
Imiquimod 5% cream
Massachusetts General Hospital
2009 Phase 1 NCT00865644 United States
Koselugo 10MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Koselugo 25MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Kybella
Massachusetts General Hospital
2024 Phase 1 NCT06300502 United States
2022 Phase 1 NCT06120036 United States
2021 Phase 1 NCT04730583 United States
Laboratory biomarker analysis
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2017 Phase 2 NCT02839720 United States
2015 Phase 1 NCT02415153 United States
2010 Phase 2 NCT01207687 United States
Lamotrigin beta
Technische Universität München, Fakultät für Medizin
2018 Phase 2 EUCTR2016-005022-10-DE Germany
Lamotrigine
Erasmus Medical Center
2014 Phase 2/Phase 3 NCT02256124 Belgium;Netherlands;Spain
Lamotrigine dispers
Erasmus MC
2018 Phase 2 EUCTR2013-003405-26-DK Belgium;Denmark;Netherlands;Spain
2017 Phase 2 EUCTR2013-003405-26-ES Belgium;Netherlands;Spain
2015 Phase 2 EUCTR2013-003405-26-BE Belgium;Denmark;Netherlands;Spain
2014 - EUCTR2013-003405-26-NL Netherlands
Lapatinib
New York University School of Medicine
2009 Phase 2 NCT00973739 United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2009 Early Phase 1 NCT00863122 United States
Lenalidomide
National Cancer Institute (NCI)
2012 Phase 2 NCT01553149 Australia;Canada;New Zealand;United States
Levetiracetam
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 1
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 2
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Levulan (5-aminolevulinic acid) photodynamic therapy - dose level 3
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Lidocaine 1% injectable solution
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
Lovastatin
Technische Universität München, Fakultät für Medizin
2018 Phase 2 EUCTR2016-005022-10-DE Germany
University of Alabama at Birmingham
2009 Phase 2 NCT00853580 Australia;United States
University of California, Los Angeles
2009 Phase 1 NCT00352599 United States
Vanderbilt University
2016 Phase 2 NCT02964884 United States
Lovastatin 60 MG
University of Coimbra
2019 - NCT03826940 Portugal
Magnetic resonance imaging
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
Washington University School of Medicine
2013 - NCT02584413 United States
Mekinist
ErasmusMC
2019 Phase 2 EUCTR2019-001317-16-NL Netherlands
VO Barnmedicin, Skånes University Hospital
2018 Phase 2 EUCTR2018-001846-32-SE Sweden
Melphalan
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Methionine
Guys' and St. Thomas' NHS Foundation Trust
2011 - EUCTR2010-019759-23-GB United Kingdom
Methotrexate
Children's Hospital of Philadelphia
2001 Phase 2 NCT00030264 United States
Methylphenidate
Hospices Civils de Lyon
2004 Phase 4 NCT00169611 France
Mirdametinib
Johns Hopkins University
2024 Phase 1/Phase 2 NCT06159166 United States
SpringWorks Therapeutics, Inc.
2022 - NCT05028166 -
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
SpringWorks Therapeutics, Inc.
2019 Phase 2 NCT03962543 United States
MRI, FDG-PET/CT scans
National Cancer Institute (NCI)
2014 Phase 1 NCT02211768 United States
N-acetyl cysteine
Children's Hospital Medical Center, Cincinnati
2020 Phase 2 NCT04481048 United States
NAC
Children's Hospital Medical Center, Cincinnati
2019 Phase 2 NCT04481035 United States
Neratinib
Scott R. Plotkin, MD, PhD
2020 Phase 2 NCT04374305 United States
Neuropsychological assessments
University Hospital, Toulouse
2009 - NCT02422732 France
Nexavar
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2011-001789-16-GB United Kingdom
NFX-179 GEL
NFlection Therapeutics, Inc.
2021 Phase 2 NCT05005845 United States
2020 Phase 2 NCT04435665 United States
Nilotinib
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2010-023508-28-GB United Kingdom
Nilotinib hydrochloride monohydrate
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Nitrous oxide
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
NPC-12G GEL
Nobelpharma
2020 Phase 3 NCT04461886 Japan
Olive OIL
Masonic Cancer Center, University of Minnesota
2022 Phase 1 NCT05363267 United States
Oncolytic measles virus encoding thyroidal sodium iodide symporter
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Other academic sham tutoring
Vanderbilt University
2016 Phase 2 NCT02964884 United States
Part 1 levulan injection
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
Part 1 levulan surface application twice with microneedling
Harry T Whelan, MD
2012 Phase 1 NCT01682811 United States
PAS-004 tablets
Pasithea Therapeutics Corp.
2025 Phase 1 NCT06961565 Australia
PD-0325901
University of Alabama at Birmingham
2014 Phase 2 NCT02096471 United States
PEG-interferon alpha-2B
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Pharmacodynamics
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Pharmacological study
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
National Cancer Institute (NCI)
2015 Phase 1 NCT02415153 United States
2012 Phase 2 NCT01553149 Australia;Canada;New Zealand;United States
Pirfenidone
Mayo Clinic
2000 Phase 2 NCT00754780 -
National Cancer Institute (NCI)
2004 Phase 2 NCT00076102 United States
2002 Phase 1 NCT00053937 United States
Polidocanol
Massachusetts General Hospital
2024 Phase 1 NCT06132165 United States
Poly iclc
University of Alabama at Birmingham
2022 Phase 2 NCT04544007 United States
Pomalidomide
National Cancer Institute (NCI)
2015 Phase 1 NCT02415153 United States
Propofol
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
PTC299
PTC Therapeutics
2009 Phase 2 NCT00911248 United States
QOL assessment, neuropsychological
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Quality-OF-life assessment
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
2010 Phase 2 NCT01207687 United States
Questionnaire administration
Mayo Clinic
2017 Phase 1 NCT02700230 United States
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
RAD001
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2011-002228-42-FR France
Assistance Publique - Hôpitaux de Paris
2012 Phase 2 NCT01490476 France
NYU Langone Health
2013 Early Phase 1 NCT01880749 United States
New York University School of Medicine
2011 Phase 2 NCT01419639 United States
Novartis Pharmaceuticals
2012 Phase 2 NCT01365468 Israel
- Phase 4 EUCTR2016-001563-36-Outside-EU/EEA Israel
RAD001, everolimus
Jonsson Comprehensive Cancer Center
2015 Phase 2 NCT01345136 United States
RAD001: everolimus
Assistance Publique - Hôpitaux de Paris
2011 Phase 2 NCT01412892 France
Radiation therapy
Sarcoma Alliance for Research through Collaboration
2005 Phase 2 NCT00304083 Canada;United States
Radiographic evaluation
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Ranibizumab
Massachusetts General Hospital
2008 Phase 0 NCT00657202 United States
Rapamycin
Department of Dermatology Graduate School of Medicine, Osaka University
2014 Phase 2,3 JPRN-UMIN000015081 Japan
Reading tutoring intervention
Vanderbilt University
2016 Phase 2 NCT02964884 United States
REC-2282
Recursion Pharmaceuticals Inc.
2022 Phase 2/Phase 3 NCT05130866 United States
Rituximab
Masonic Cancer Center, University of Minnesota
2023 Phase 2 NCT05735717 United States
Saline solution
Fundação Educacional Serra dos Órgãos
2017 Phase 2 NCT03090971 Brazil
Selumetinib
AeRang Kim
2025 Phase 1/Phase 2 NCT06735820 United States
AstraZeneca
2023 Phase 2 NCT05825365 China
2021 Phase 1 NCT05101148 Poland;Russian Federation;Spain;United States
2021 Phase 3 NCT04924608 Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2020 Phase 1 NCT04590235 China
2020 Phase 1 NCT04495127 Japan
2017 - NCT03259633 United States
AstraZeneca KK
2020 Phase 1 JPRN-jRCT2080225326 Japan;North America
Children's Hospital Medical Center, Cincinnati
2017 Phase 2 NCT03095248 United States
Great Ormond Street Hospital for Children NHS Foundation Trust
2019 Phase 1/Phase 2 NCT03326388 United Kingdom
Kobayashi Hiroshi
2023 Phase 1-2 JPRN-jRCT2071220074 Germany;Italy;Japan;Netherland;Russia;Spain;USA
2022 Phase 3 JPRN-jRCT2041210036 Australia;Brasil;Canada;China;France;Germany;Italy;Japan;Poland;Russia;Spain;UK;USA
National Cancer Institute (NCI)
2016 Phase 2 NCT02407405 United States
2015 Phase 2 NCT02644512 United States
2010 Phase 1/Phase 2 NCT01089101 United States
Sarcoma Alliance for Research through Collaboration
2019 Phase 2 NCT03433183 United States
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000036770 China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024 Phase 2 NCT06621082 -
2024 Phase 2 NCT06620354 -
University of Alabama at Birmingham
2025 Phase 2 NCT06188741 -
2017 Phase 2 NCT03105258 United States
West China Hospital
2025 Phase 2 NCT06763315 China
Selumetinib (AZD6244 HYD sulfate) 25MG/M2
National Cancer Institute (NCI)
2017 Phase 2 NCT03109301 United States
Selumetinib (AZD6244 HYD sulfate) 50MG/dose
National Cancer Institute (NCI)
2017 Phase 2 NCT03109301 United States
Selumetinib 10MG capsule
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib 25MG capsule
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib capsule formulation
AstraZeneca
2022 Phase 1/Phase 2 NCT05309668 Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib capsules 10MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib capsules 25MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib granule formulation
AstraZeneca
2022 Phase 1/Phase 2 NCT05309668 Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib granules IN sprinkle capsules FOR opening 5 MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
Selumetinib granules IN sprinkle capsules FOR opening 7.5 MG
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
Selumetinib HYD-sulfate
ASTRAZENECA AB
2021 Phase 3 EUCTR2020-005607-39-IT Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
AstraZeneca AB
2022 Phase 1;Phase 2 EUCTR2020-005608-20-NL Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2022 Phase 1;Phase 2 EUCTR2020-005608-20-ES Germany;Italy;Netherlands;Russian Federation;Spain;United States
2022 Phase 3 EUCTR2020-005607-39-PL Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
2021 Phase 1;Phase 2 EUCTR2020-005608-20-DE Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-FR Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
2021 Phase 3 EUCTR2020-005607-39-ES Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States
Selumetinib HYD-sulphate
Great Ormond Street Hospital
2018 Phase 1;Phase 2 EUCTR2017-002635-41-GB United Kingdom
Selumetinib oral capsule
Girish Dhall, MD
2025 Phase 1 NCT06502171 United States
Selumetinib sulfate
AstraZeneca AB
2021 Phase 1 EUCTR2020-005648-52-PL Poland;Russian Federation;Spain;United States
2021 Phase 1 EUCTR2020-005648-52-ES Poland;Russian Federation;Spain;United States
Great Ormond Street Hospital
2018 Phase 1;Phase 2 EUCTR2017-002635-41-GB United Kingdom
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
2017 Phase 2 NCT02839720 United States
Sevoflurane
Medical College of Wisconsin
2018 Phase 4 NCT03513757 United States
Simvastatin
Erasmus MC - Department of Pediatrics
2009 - EUCTR2009-010965-22-NL Netherlands
Simvastatin 20MG/5ML oral suspension
Central Manchester University Hospitals NHS Foundation Trust
2013 Phase 2 EUCTR2012-005742-38-GB United Kingdom
Single photon emission computed tomography
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Sirolimus
Osaka University Hospital
2016 Phase 2 JPRN-UMIN000021030 Japan
Sarcoma Alliance for Research through Collaboration
2019 Phase 2 NCT03433183 United States
University of Alabama at Birmingham
2008 Phase 2 NCT00652990 United States
2008 Phase 2 NCT00634270 United States
Skincerity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States
Skinercity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States
Sodium chloride
Kiyoshi Saito
2019 Phase 2 JPRN-jRCT2080224914 Japan
Sorafenib
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2011-001789-16-GB United Kingdom
ST002
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025 - NCT06834438 China
Sunitinib
Memorial Sloan Kettering Cancer Center
2007 Phase 2 NCT00589784 United States
Sutent®/sunitinib
Indiana University
2012 Phase 2 NCT01402817 United States
Tarceva and rapamycin
Roger Packer
2007 Phase 1 NCT00901849 United States
Tasigna
Indiana University
2011 Early Phase 1 NCT01275586 United States
Plymouth Hospital NHS Trust
2011 Phase 4 EUCTR2010-023508-28-GB United Kingdom
Tasigna 150MG
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Tasigna 200MG
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Tasigna 50 MG
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Temozolomide
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Temsirolimus
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Test group (group A): FCN-159 8 MG, orally, once daily
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
2023 Phase 3 NCT05913037 China
Tipifarnib
National Cancer Institute (NCI)
2001 Phase 2 NCT00021541 Germany;United States
Toxicity, pharmacokinetics
National Cancer Institute (NCI)
2008 Phase 1 NCT00727233 United States
Trametinib
National Cancer Institute (NCI)
2018 Phase 2 NCT03190915 United States
Novartis Pharmaceuticals
2019 Phase 4 NCT03975829 Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
Pediatric Brain Tumor Consortium
2020 Phase 1/Phase 2 NCT04201457 United States
Region Skane
2019 Phase 2 NCT03741101 Sweden
Therapeutic Advances in Childhood Leukemia Consortium
2024 Phase 1/Phase 2 NCT05849662 United States
University of California, San Francisco
2018 Phase 2 NCT03232892 United States
Treatment A
AstraZeneca
2018 Phase 1 NCT03649165 United States
Treatment B
AstraZeneca
2018 Phase 1 NCT03649165 United States
Treatment C
AstraZeneca
2018 Phase 1 NCT03649165 United States
Treatment D
AstraZeneca
2018 Phase 1 NCT03649165 United States
Ultrasound imaging
Mayo Clinic
2017 Phase 1 NCT02700230 United States
Unknown
Leiden University Medical Center
2021 Phase 2 EUCTR2020-000156-35-NL Netherlands
Valproic acid
M.D. Anderson Cancer Center
2012 Phase 1 NCT01552434 United States
Vehicle GEL
NFlection Therapeutics, Inc.
2021 Phase 2 NCT05005845 United States
2020 Phase 2 NCT04435665 United States
Vinblastine
Children's Hospital of Philadelphia
2001 Phase 2 NCT00030264 United States
Vinblastine sulfate
Children's Oncology Group
2006 Phase 1 NCT00352495 Canada;United States
Vinblastine sulphate
Gustave Roussy
2013 Phase 2 EUCTR2012-003005-10-DK Denmark;France;Netherlands;Spain;Switzerland
Vincristine sulfate
National Cancer Institute (NCI)
2020 Phase 3 NCT04166409 Canada;Puerto Rico;United States
2020 Phase 3 NCT03871257 Canada;Puerto Rico;United States
Spectrum Health Hospitals
2008 Phase 2 NCT00846430 United States
Votubia
Novartis Pharmaceuticals
- Phase 4 EUCTR2016-001563-36-Outside-EU/EEA Israel
Xalkori
Medical University of Warsaw
2023 Phase 2 EUCTR2021-005770-26-PL Poland